Genprex, Inc. (NASDAQ:GNPX)

Genprex, Inc. (NASDAQ:GNPX)


Share Price
$ 1.18
Change
0.08 (7.27 %)
Market Cap
$18.41 m
Proactive Investors - Run By Investors For Investors

Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer. Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres...

EPIC: GNPX
Market: NASDAQ:GNPX
52-week High/Low: $7.88 / $0.95
Sector: Pharmaceuticals
Market Cap: $18.41 m
Website: www.genprex.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Genprex, Inc.


Genprex, Inc. Snapshot

Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based on our novel proprietary technology platform, including our initial product candidate - Oncoprex™ immunogene therapy - or, Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. We are currently conducting the second phase of a Phase I/II clinical trial at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Rodney Varner
Executive Chairman & CEO | Genprex Inc

Mr. Varner has more than thirty years of legal experience with large and small law firms, and as outside general counsel of a NASDAQ traded company. Rodney represents for-profit and non-profit companies at the Board of Directors or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Rodney serves as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation.

Rodney is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for Fifth Circuit and the United States Tax Court. He is a registered securities representative and owner of a company that is a licensed securities broker-dealer. He maintains Series 7, 24, 63, and 79 securities registrations.

Rodney is a member of the Board of Directors of Texas Healthcare and Bioscience Institute (THBI), and serves as its General Counsel. He is also a founder and member of the Board of Directors of Texas Medical Device Alliance.

Rodney is a graduate of the University of Texas School of Law (J.D., 1978); and Texas A & M University (BBA, with high honors, 1976.)

Ryan Confer
Chief Financial Officer | Genprex Inc

Mr. Confer has more than ten years of experience launching and developing emerging technology companies. Previously, he served as an International Business Development Strategist for the University of Texas at Austin where he focused on evaluating the commercialization potential of nascent technologies for domestic and international markets. Prior to his experience at the University of Texas, Ryan served as an investment manager for a $500 million early-stage technology investment fund where he analyzed market opportunities, identified and negotiated operational milestones, and negotiated deal terms for approximately 100 early-stage technology companies.

Ryan has provided strategic advisory services and served as a board member for several Austin-based technology startups. He has served as an advisor for several Texas-based incubator and accelerators and regularly serves as a mentor and judge for the Jon Brumley Texas Venture Labs at the University of Texas at Austin. Ryan is a graduate of McCombs School of Business at the University of Texas at Austin (MS in Technology Commercialization, 2009) and Bloomsburg University of Pennsylvania (BSBA in Finance and Legal Studies, 2005).

Elizabeth Han
Corporate Counsel | Genprex Inc

Elizabeth Han, JD joined Genprex from Norton Rose Fulbright, LLP in 2016. Elizabeth handles a variety of legal matters for the company. While at Norton Rose Fulbright, she focused her practice primarily on health care compliance and regulatory matters and represented a number of large medical device manufacturers, pharmaceutical companies, and hospitals. She has extensive experience in matters relating to the Federal Anti-Kickback Statute, the False Claims Act, and the Stark Law.

Elizabeth received her J.D. from the University of Michigan School of Law and her B.A. from Columbia University. Prior to working at Norton Rose Fulbright, she served as a judicial intern for the Honorable Judge Lee Yeakel at the U.S. District Court for the Western District of Texas. She also worked as a student attorney for the University of Michigan’s Child Welfare Appellate Clinic where she assisted parents with child custody issues. She is a member of the State Bar of Texas.

Julien Pham
Chief Operating Officer | Genprex Inc

Julien L. Pham, MD, MPH, has over fifteen (15) years of leadership experience in clinical settings and in emerging medical technology companies.  During this time, he has held various research and teaching positions including Chief Residency in Internal Medicine and Pediatrics, and has received multiple awards including excellence in teaching awards from AOA and Harvard Medical School.  He is a board-certified Internal Medicine doctor and Nephrologist, who has received NIH research funding for translational research while at Harvard, and has published in basic science, translational, and health policy fields. Dr. Pham most recently co-founded and served as Chief Medical Officer of RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases.  Prior to RubiconMD, he served on faculty at Harvard Medical School’s Brigham and Women’s Hospital with an appointment at Dana Farber Cancer Institute. He received his MD from the University of Washington School of Medicine and his MPH at the Harvard School of Public health.

For stock data please click here

Headquaters

Dell Medical Center
Health Discovery Building
1701 Trinity Street, Mail Code Z1400
Suite 3.322
Austin, TX 78712-1885

Phone: (512) 537-7997

Market Reports Including GNPX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use